Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULMGet Rating) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 3,700 shares, a growth of 184.6% from the April 30th total of 1,300 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 18,600 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

A number of research analysts have commented on PULM shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Pulmatrix in a report on Tuesday, February 7th. StockNews.com began coverage on Pulmatrix in a research report on Wednesday. They set a “hold” rating for the company.

Hedge Funds Weigh In On Pulmatrix

Several large investors have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new position in Pulmatrix in the first quarter valued at about $73,000. Mariner LLC acquired a new stake in shares of Pulmatrix in the fourth quarter valued at about $97,000. Citadel Advisors LLC acquired a new stake in shares of Pulmatrix in the second quarter valued at about $141,000. Finally, Renaissance Technologies LLC increased its stake in shares of Pulmatrix by 7.3% in the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock valued at $560,000 after buying an additional 8,300 shares during the period. 15.69% of the stock is currently owned by institutional investors.

Pulmatrix Stock Up 3.0 %

Shares of NASDAQ:PULM traded up $0.08 during trading on Friday, reaching $2.75. 11,706 shares of the company traded hands, compared to its average volume of 29,697. The company’s 50 day moving average is $2.88 and its two-hundred day moving average is $3.43. The firm has a market capitalization of $10.04 million, a PE ratio of -0.53 and a beta of 0.76. Pulmatrix has a 52 week low of $2.63 and a 52 week high of $7.50.

Pulmatrix (NASDAQ:PULMGet Rating) last announced its quarterly earnings data on Thursday, March 30th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.44) by $0.30. Pulmatrix had a negative return on equity of 55.65% and a negative net margin of 285.66%. The business had revenue of $1.71 million during the quarter, compared to the consensus estimate of $1.87 million. As a group, research analysts anticipate that Pulmatrix will post -4.94 EPS for the current year.

About Pulmatrix

(Get Rating)

Pulmatrix, Inc is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Read More

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.